<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126541</url>
  </required_header>
  <id_info>
    <org_study_id>ML19895</org_study_id>
    <nct_id>NCT01126541</nct_id>
  </id_info>
  <brief_title>SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy</brief_title>
  <official_title>A Comparative Study to Assess the Effect of Retreatment With 2 Doses of MabThera on Disease Activity Score in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to antiTNF-alfa Therapy.(SMART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will compare the efficacy and safety of re-treatment with 2 doses of MabThera
      (rituximab) in patients with active rheumatoid arthritis (RA) who have previously experienced
      an inadequate response or intolerance to anti-tumor necrosis factor (anti-TNF) therapies
      etanercept, infliximab or adalimumab therapy. All patients will receive infusions of 1000 mg
      intravenous (IV) MabThera on Days 1 and 15; at Week 24 patients who have demonstrated a
      moderate or good response will be randomized to receive re-treatment with either 1 or 2
      additional infusions of 1000 mg IV MabThera. The anticipated time on study treatment is 2+
      years, and the target sample size is 100-500 individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS28-CRP) Area Under the Curve (AUC) at Week 104</measure>
    <time_frame>Week 104</time_frame>
    <description>DAS28-CRP was based on joint counts, overall participant assessment, and serum CRP levels (measured in milligrams per liter [mg/L]) at each visit. Joint counts included swollen joint count (SJC) and tender joint count (TJC). Total score range was 0 to 9.4; a higher score indicated more disease activity. DAS28-CRP less than or equal to (≤)3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity, and less than (&lt;)2.6 equals (=) remission. The AUC of all DAS28-CRP values between Day 1 and Week 104 (15 values of protocol visits) was calculated using the trapeze method (AUC between t1 and t2=(t2-t1)*((DAS28-CRP at t1 + DAS28-CRP at t2)/2). The true visit dates were used to calculate the time between 2 DAS28-CRP evaluations. All the AUC were censored at Week 104 (linear extrapolation using the 2 last DAS28-CRP values (Weeks 96 and 104) to obtain the &quot;true&quot; DAS28-CRP value at the &quot;true&quot; Week 104).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DAS28-CRP During the Initial Treatment</measure>
    <time_frame>Days 1 and 15, and Weeks 6, 12, and 24</time_frame>
    <description>Mean DAS28-CRP at Week 24 of the Initial Treatment study. DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-CRP ≤3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity, and &lt;2.6=remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28-CRP and Changes From Baseline to Week 24 in DAS28-CRP by Retreatment Course</measure>
    <time_frame>Day 1, 24 weeks following each infusion up to 72 Weeks</time_frame>
    <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity, and &lt;2.6=remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Clinical Remission (DAS28-CRP &lt;2.6) or Low Disease Activity (DAS28-CRP ≤3.2)</measure>
    <time_frame>Week 24 of the Initial Treatment, 24 weeks after first retreatment, and 24 weeks after second retreatment</time_frame>
    <description>Percentage of participants with clinical remission and low disease activity as measured by DAS28-CRP for Arm A and Arm B at Week 24 of the Initial Treatment, at 24 weeks after first re-treatment, and at 24 weeks after second retreatment. DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity and &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28-CRP AUC Weighted Time</measure>
    <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
    <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity, and &lt;2.6=remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve DAS28-CRP Remission After the First Course</measure>
    <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
    <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP &lt;2.6=remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve DAS28-CRP Remission After Retreatment</measure>
    <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
    <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP &lt;2.6=remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve DAS28-CRP ≤3.2 After the First Course of Treatment</measure>
    <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
    <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve DAS28-CRP ≤3.2 After Retreatment</measure>
    <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
    <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of DAS28-CRP Remission After the First Course of Treatment</measure>
    <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
    <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP &lt;2.6=remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of DAS28-CRP Remission After Retreatment</measure>
    <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
    <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP &lt;2.6=remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of DAS28-CRP ≤3.2 After the First Course of Treatment</measure>
    <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
    <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of DAS28-CRP ≤3.2 After Retreatment</measure>
    <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
    <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20%, 50%, and 70% Improvement (ACR20/ACR50/ACR70)</measure>
    <time_frame>Week 24 of the initial treatment, 24 weeks after first retreatment, and 24 weeks after second retreatment</time_frame>
    <description>ACR20/50/70 response defined as ≥20%, 50%, or 70% improvement, respectively, in TJC and SJC, and ≥20%, 50%, or 70% improvement, respectively, in at least 3 of 5 remaining ACR core measures: Patient Global Assessment of Pain, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity (on a visual analog scale [VAS]); Health Assessment Questionnaire-Disability Index (HAQ-DI); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Response During Initial Treatment by European League Against Rheumatism (EULAR) Category</measure>
    <time_frame>Day 15, Weeks 6, 12, and 24</time_frame>
    <description>DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders = change from baseline &gt;1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline &gt;1.2 with a DAS28 score of &gt;3.2 to ≤ 5.1 or change from baseline &gt;0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline &gt;0.6 and ≤ 1.2 with a DAS28 score of &gt;5.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Response During Retreatment by EULAR Category</measure>
    <time_frame>Week 24, 24 weeks after 1st retreatment, 24 weeks after 2nd retreatment</time_frame>
    <description>DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders = change from baseline &gt;1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline &gt;1.2 with a DAS28 score of &gt;3.2 to ≤ 5.1 or change from baseline &gt;0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline &gt;0.6 and ≤ 1.2 with a DAS28 score of &gt;5.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Rheumatoid Factor (RF) at 24 Weeks After Treatment</measure>
    <time_frame>Week 24 of the initial treatment, 24 weeks after first re-treatment, and 24 weeks after second retreatment</time_frame>
    <description>RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 international units per milliliter (IU/mL) is considered positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at 24 Weeks After Treatment</measure>
    <time_frame>Week 24 of the initial treatment, 24 weeks after first re-treatment, and 24 weeks after second retreatment</time_frame>
    <description>Anti-CCP antibodies are auto antibodies (antibodies directed against 1 or more of an individual's own proteins) that are frequently detected in the blood of rheumatoid arthritis participants. Anti-CCP antibodies value higher than 10 U/mL is considered positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment of Disease Activity</measure>
    <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
    <description>The Physician's Global Assessment of disease activity is assessed on a 0 to 100 millimeter (mm) horizontal VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as &quot;no disease activity&quot; (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as &quot;maximum disease activity&quot; (maximum arthritis disease activity). Physicians were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high disease activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Disease Activity</measure>
    <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
    <description>The Patient's Global Assessment of Disease Activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as &quot;no disease activity&quot; (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as &quot;maximum disease activity&quot; (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment of Pain</measure>
    <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
    <description>The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as &quot;no pain&quot; and the right-hand extreme equals 100 mm as &quot;unbearable pain&quot;. Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high pain levels).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment of Fatigue</measure>
    <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
    <description>Participants were asked to rate their level of fatigue over the last 7 days on a 100-mm VAS. The left-hand extreme of the line equals 0 mm, and is described as &quot;no fatigue&quot; and the right-hand extreme equals 100 mm as &quot;extreme fatigue&quot;. Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high levels of fatigue).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisone Intake AUC (Time- and Weight-Weighted)</measure>
    <time_frame>Day 1 (each infusion), Week 24, Week 104</time_frame>
    <description>All cortisone intakes (in mg) were taken into account (oral, IV [including the cortisone administration before the rituximab infusion], intramuscular, and intra-articular).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Mean Dose of Cortisone Between Week 24 and Week 104</measure>
    <time_frame>Week 24 to Week 104</time_frame>
    <description>All cortisone intakes were taken into account, including oral, IV (including the cortisone administration before the rituximab infusion), intramuscular and intra-articular.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAQ-DI Scores</measure>
    <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
    <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 12 (SF-12) Physical Health Composite Score</measure>
    <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
    <description>Physical and Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12 Mental Health Composite Score</measure>
    <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
    <description>Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcomes Study Sleep Scale (MOS-Sleep) Composite Sleep Problems 6 (SLP6) Index</measure>
    <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
    <description>The MOS Sleep Scale measures most constructs of sleep. The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities. The SLP6 index is comprised of 6 items: provides a summary of sleep problems and contains questions from the sleep disturbance, sleep adequacy, respiratory impairment, and somnolence domains. The SLP6 index score ranges between 0 and 100, with higher values corresponding to more sleep problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Acceptable Disease Activity Symptom State Assessed Using Patient Acceptable and Unacceptable Symptom State (PASS)</measure>
    <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
    <description>Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of disease activity they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered &quot;unacceptable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Disease Activity in Participants Reporting Acceptable Symptoms Using PASS</measure>
    <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
    <description>The Patient's Global Assessment of Disease Activity assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as &quot;no disease activity&quot; (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as &quot;maximum disease activity&quot; (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Minimum Clinically Important Improvement (MCII) in Disease Activity</measure>
    <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
    <description>Participants were asked how their disease activity had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse-more disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Assessment of Disease Activity in Participants With MCII</measure>
    <time_frame>Baseline, Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
    <description>The Patient's Global Assessment of Disease Activity was assessed in participants reporting MCII on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as &quot;no disease activity&quot; (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as &quot;maximum disease activity&quot; (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Acceptable Symptom State in Functioning Assessed Using PASS</measure>
    <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
    <description>Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of function they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of function they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered &quot;unacceptable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAQ-DI Scores in Participants Reporting Acceptable Function Using PASS</measure>
    <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
    <description>HAQ-DI was assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours). HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With MCII in Functioning</measure>
    <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
    <description>Participants were asked how their functioning had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI in Participants With MCII</measure>
    <time_frame>Baseline, Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
    <description>HAQ-DI was assessed in participants with MCII. HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Acceptable Symptom State in Pain Assessed Using PASS</measure>
    <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
    <description>Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of pain they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered &quot;unacceptable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Pain in Participants Reporting Acceptable Symptoms Using PASS</measure>
    <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
    <description>Patient Global Assessment of Pain assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as &quot;no pain&quot; and the right-hand extreme equals 100 mm as &quot;unbearable pain&quot;. Higher values correspond to worst state of participant (high pain levels).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With MCII in Pain</measure>
    <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
    <description>Participants were asked how their pain had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Assessment of Pain in Participants With MCII</measure>
    <time_frame>Baseline, Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
    <description>The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as &quot;no pain&quot; and the right-hand extreme equals 100 mm as &quot;unbearable pain&quot;. Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high pain levels).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg IV rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 1000 mg IV rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Arm A: 1000 mg IV (one infusion) every 2 months \nArm B: 2 x 1000 mg IV (2 infusions) every 2 months</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>MabThera/Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients &gt;18 years of age

          -  RA for &gt;=6 months

          -  Receiving outpatient treatment

          -  Ongoing treatment with methotrexate for &gt;=3 months, stable for &gt;=1 month

          -  Inadequate response or intolerance to etanercept, infliximab or adalimumab

        Exclusion Criteria:

          -  Previous treatment with MabThera

          -  Concurrent treatment with any anti TNF-alfa therapy or biologic therapy

          -  Previous treatment with any investigational cell-depleting therapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Chair</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Abbeville</city>
        <zip>80142</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Agen</city>
        <zip>47923</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aix En Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aix Les Bains</city>
        <zip>73106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfort</city>
        <zip>90016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berck</city>
        <zip>62600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bois-guillaume</city>
        <zip>76233</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boulogne-billancourt</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cahors</city>
        <zip>46005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corbeil-essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Echirolles</city>
        <zip>38434</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Libourne</city>
        <zip>33505</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lievin</city>
        <zip>62800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lomme</city>
        <zip>59462</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69365</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montivilliers</city>
        <zip>76290</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Narbonne</city>
        <zip>11108</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>PAU</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-etienne</city>
        <zip>4200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulon</city>
        <zip>83100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2010</study_first_submitted>
  <study_first_submitted_qc>May 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <results_first_submitted>July 15, 2014</results_first_submitted>
  <results_first_submitted_qc>September 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2014</results_first_posted>
  <last_update_submitted>September 10, 2014</last_update_submitted>
  <last_update_submitted_qc>September 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Randomized Retreatment Arm A: Rituximab 1000 Milligrams (mg)</title>
          <description>Participants received rituximab 1000 mg intravenously (IV) on Days 1 and 15. After Week 24, if Disease Activity Score based on 28-Joint Count (DAS28) was greater than (&gt;)3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and methotrexate (MTX) ≥10 milligrams per week (mg/week) by mouth or parenteral throughout course of treatment.</description>
        </group>
        <group group_id="P2">
          <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
          <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
        </group>
        <group group_id="P3">
          <title>Nonrandomized: Rituximab 1000 mg</title>
          <description>Participants received rituximab 1000 mg IV on Days 1 and 15, methylprednisolone 100 mg IV at 30 minutes before each rituximab infusion, and MTX ≥10 mg/week by mouth or parenterally throughout treatment course.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason or other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
          <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
        </group>
        <group group_id="B2">
          <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
          <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
        </group>
        <group group_id="B3">
          <title>Nonrandomized: Rituximab 1000 mg</title>
          <description>Participants received rituximab 1000 mg IV on Days 1 and 15, methylprednisolone 100 mg IV at 30 minutes before each rituximab infusion, and MTX ≥10 mg/week by mouth or parenterally throughout treatment course.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="81"/>
            <count group_id="B4" value="224"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.5" spread="11.5"/>
                    <measurement group_id="B2" value="57.2" spread="10.4"/>
                    <measurement group_id="B3" value="56.1" spread="11.2"/>
                    <measurement group_id="B4" value="56.0" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>DAS28-CRP During the Initial Treatment</title>
        <description>Mean DAS28-CRP at Week 24 of the Initial Treatment study. DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-CRP ≤3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity, and &lt;2.6=remission.</description>
        <time_frame>Days 1 and 15, and Weeks 6, 12, and 24</time_frame>
        <population>Overall population: all participants with at least one treatment intake.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Group</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants were randomized to receive a single rituximab 1000 mg IV infusion (Retreatment Arm A) or 2 x rituximab 1000 mg IV infusions 15 days apart (Retreatment Arm B). All participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Nonrandomized Group</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15, methylprednisolone 100 mg IV at 30 minutes before each rituximab infusion, and MTX ≥10 mg/week by mouth or parenterally throughout treatment course.</description>
          </group>
        </group_list>
        <measure>
          <title>DAS28-CRP During the Initial Treatment</title>
          <description>Mean DAS28-CRP at Week 24 of the Initial Treatment study. DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-CRP ≤3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity, and &lt;2.6=remission.</description>
          <population>Overall population: all participants with at least one treatment intake.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Course, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.82" spread="0.85"/>
                    <measurement group_id="O2" value="5.77" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Course, Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" spread="1.09"/>
                    <measurement group_id="O2" value="5.42" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up, Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.69" spread="0.95"/>
                    <measurement group_id="O2" value="5.12" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up, Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.13" spread="0.91"/>
                    <measurement group_id="O2" value="5.00" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65" spread="0.85"/>
                    <measurement group_id="O2" value="5.24" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DAS28-CRP and Changes From Baseline to Week 24 in DAS28-CRP by Retreatment Course</title>
        <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity, and &lt;2.6=remission.</description>
        <time_frame>Day 1, 24 weeks following each infusion up to 72 Weeks</time_frame>
        <population>ITT Population; number (n)=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>DAS28-CRP and Changes From Baseline to Week 24 in DAS28-CRP by Retreatment Course</title>
          <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity, and &lt;2.6=remission.</description>
          <population>ITT Population; number (n)=number of participants assessed for the specified parameter at a given visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial treatment, Day 1 (n=70,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.79" spread="0.85"/>
                    <measurement group_id="O2" value="5.84" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial treatment, Week 24 (n=70,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="0.89"/>
                    <measurement group_id="O2" value="3.73" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24 (n=70,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.22" spread="0.96"/>
                    <measurement group_id="O2" value="-2.11" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Day 1 (n=66,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="0.91"/>
                    <measurement group_id="O2" value="4.45" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=66,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="1.15"/>
                    <measurement group_id="O2" value="3.69" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Change at Week 24 (n=66,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="1.15"/>
                    <measurement group_id="O2" value="-0.79" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd retreatment, Day 1 (n=49,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.60" spread="0.87"/>
                    <measurement group_id="O2" value="4.55" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd retreatment, Week 24 (n=41,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" spread="1.10"/>
                    <measurement group_id="O2" value="3.76" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd retreatment, Change at Week 24 (n=41,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="1.17"/>
                    <measurement group_id="O2" value="-0.78" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 1 to Week 24 (initial treatment)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Primary objective to demonstrate noninferiority of retreatment with one 1000 mg rituximab infusion. Mean ±SD of the DAS28-CRP AUC at 24 months = 2218 ±967 (based on EDWARDS, REFLEX and DANCER study data). H0 (null hypothesis): Arm B – Arm A &gt;20%. H1: Arm B – Arm A ≤ 20%. Power = 80%; Larger difference clinically acceptable = 20% = 444; Significance level of 2.5% (one-sided).</non_inferiority_desc>
            <p_value>0.465</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Arm A vs. Arm B: Change from 1st retreatment to 24 weeks after</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Primary objective to demonstrate noninferiority of retreatment with one 1000 mg rituximab infusion. Mean ±SD of the DAS28-CRP AUC at 24 months = 2218 ±967 (based on EDWARDS, REFLEX and DANCER study data). H0 (null hypothesis): Arm B – Arm A &gt;20%. H1: Arm B – Arm A ≤ 20%. Power = 80%; Larger difference clinically acceptable = 20% = 444; Significance level of 2.5% (one-sided)</non_inferiority_desc>
            <p_value>0.161</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Arm A vs. Arm B: Change from 2nd retreatment to 24 weeks after</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Primary objective to demonstrate noninferiority of retreatment with one 1000 mg rituximab infusion. Mean ±SD of the DAS28-CRP AUC at 24 months = 2218 ±967 (based on EDWARDS, REFLEX and DANCER study data). H0 (null hypothesis): Arm B – Arm A &gt;20%. H1: Arm B – Arm A ≤ 20%. Power = 80%; Larger difference clinically acceptable = 20% = 444; Significance level of 2.5% (one-sided)</non_inferiority_desc>
            <p_value>0.524</p_value>
            <method>Student t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS28-CRP) Area Under the Curve (AUC) at Week 104</title>
        <description>DAS28-CRP was based on joint counts, overall participant assessment, and serum CRP levels (measured in milligrams per liter [mg/L]) at each visit. Joint counts included swollen joint count (SJC) and tender joint count (TJC). Total score range was 0 to 9.4; a higher score indicated more disease activity. DAS28-CRP less than or equal to (≤)3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity, and less than (&lt;)2.6 equals (=) remission. The AUC of all DAS28-CRP values between Day 1 and Week 104 (15 values of protocol visits) was calculated using the trapeze method (AUC between t1 and t2=(t2-t1)*((DAS28-CRP at t1 + DAS28-CRP at t2)/2). The true visit dates were used to calculate the time between 2 DAS28-CRP evaluations. All the AUC were censored at Week 104 (linear extrapolation using the 2 last DAS28-CRP values (Weeks 96 and 104) to obtain the “true” DAS28-CRP value at the “true” Week 104).</description>
        <time_frame>Week 104</time_frame>
        <population>Per Protocol (PP) population: all randomized participants in the Intent-to-Treat (ITT) population (defined as all randomized participants) without major protocol violations. Participants were grouped according to their initially assigned treatment arm irrespective of the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS28-CRP) Area Under the Curve (AUC) at Week 104</title>
          <description>DAS28-CRP was based on joint counts, overall participant assessment, and serum CRP levels (measured in milligrams per liter [mg/L]) at each visit. Joint counts included swollen joint count (SJC) and tender joint count (TJC). Total score range was 0 to 9.4; a higher score indicated more disease activity. DAS28-CRP less than or equal to (≤)3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity, and less than (&lt;)2.6 equals (=) remission. The AUC of all DAS28-CRP values between Day 1 and Week 104 (15 values of protocol visits) was calculated using the trapeze method (AUC between t1 and t2=(t2-t1)*((DAS28-CRP at t1 + DAS28-CRP at t2)/2). The true visit dates were used to calculate the time between 2 DAS28-CRP evaluations. All the AUC were censored at Week 104 (linear extrapolation using the 2 last DAS28-CRP values (Weeks 96 and 104) to obtain the “true” DAS28-CRP value at the “true” Week 104).</description>
          <population>Per Protocol (PP) population: all randomized participants in the Intent-to-Treat (ITT) population (defined as all randomized participants) without major protocol violations. Participants were grouped according to their initially assigned treatment arm irrespective of the treatment actually received.</population>
          <units>score on a scale*week</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2761.4" spread="507.8"/>
                    <measurement group_id="O2" value="2666.0" spread="490.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Primary objective to demonstrate noninferiority of retreatment with one 1000 mg rituximab infusion. Mean plus or minus (±)SD of the DAS28-CRP AUC at 24 months = 2218 ±967 (based on EDWARDS, REFLEX and DANCER study data). H0 (null hypothesis): Arm B – Arm A &gt;20%. H1: Arm B – Arm A ≤ 20%. Power = 80%; Larger difference clinically acceptable = 20% = 444; Significance level of 2.5% (one-sided)</non_inferiority_desc>
            <param_type>Adjusted difference</param_type>
            <param_value>51.38</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>92.00</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-131.22</ci_lower_limit>
            <ci_upper_limit>233.98</ci_upper_limit>
            <estimate_desc>Covariate analysis with baseline DAS28-CRP value as covariate</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Clinical Remission (DAS28-CRP &lt;2.6) or Low Disease Activity (DAS28-CRP ≤3.2)</title>
        <description>Percentage of participants with clinical remission and low disease activity as measured by DAS28-CRP for Arm A and Arm B at Week 24 of the Initial Treatment, at 24 weeks after first re-treatment, and at 24 weeks after second retreatment. DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity and &lt;2.6 = remission.</description>
        <time_frame>Week 24 of the Initial Treatment, 24 weeks after first retreatment, and 24 weeks after second retreatment</time_frame>
        <population>ITT Population; n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Clinical Remission (DAS28-CRP &lt;2.6) or Low Disease Activity (DAS28-CRP ≤3.2)</title>
          <description>Percentage of participants with clinical remission and low disease activity as measured by DAS28-CRP for Arm A and Arm B at Week 24 of the Initial Treatment, at 24 weeks after first re-treatment, and at 24 weeks after second retreatment. DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity and &lt;2.6 = remission.</description>
          <population>ITT Population; n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Remission: Initial Treatment, Week 24 (n=70,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission: 1st Re-treatment, Week 24 (n=66,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission: 2nd Retreatment, Week 24 (n=43,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low activity: Initial Treatment, Week 24 (n=70,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1"/>
                    <measurement group_id="O2" value="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low activity: 1st Retreatment, Week 24 (n=66,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8"/>
                    <measurement group_id="O2" value="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low activity: 2nd Retreatment, Week 24 (n=43,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DAS28-CRP AUC Weighted Time</title>
        <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity, and &lt;2.6=remission.</description>
        <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>DAS28-CRP AUC Weighted Time</title>
          <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity, and &lt;2.6=remission.</description>
          <population>ITT population</population>
          <units>units on a scale*week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" spread="0.71"/>
                    <measurement group_id="O2" value="3.88" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve DAS28-CRP Remission After the First Course</title>
        <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP &lt;2.6=remission.</description>
        <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Group</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants were randomized to receive a single rituximab 1000 mg IV infusion (Retreatment Arm A) or 2 x rituximab 1000 mg IV infusions 15 days apart (Retreatment Arm B). All participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve DAS28-CRP Remission After the First Course</title>
          <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP &lt;2.6=remission.</description>
          <population>ITT population</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" lower_limit="34.9">Upper limit of the 95% confidence interval (CI) for the time to remission could not be calculated due to an insufficient number of events occurring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve DAS28-CRP Remission After Retreatment</title>
        <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP &lt;2.6=remission.</description>
        <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
        <population>ITT population; n=number of participants assessed at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve DAS28-CRP Remission After Retreatment</title>
          <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP &lt;2.6=remission.</description>
          <population>ITT population; n=number of participants assessed at a given visit.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st retreatment (n=66,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Time to remission could not be determined due to an insufficient number of events occurring.</measurement>
                    <measurement group_id="O2" value="78.1" lower_limit="37.0">Upper limit of the 95% CI for time to remission could not be determined due to an insufficient number of events occurring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd retreatment (n=49,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Time to remission could not be determined due to an insufficient number of events occurring.</measurement>
                    <measurement group_id="O2" value="NA">Time to remission could not be determined due to an insufficient number of events occurring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve DAS28-CRP ≤3.2 After the First Course of Treatment</title>
        <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.</description>
        <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Group</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants were randomized to receive a single rituximab 1000 mg IV infusion (Retreatment Arm A) or 2 x rituximab 1000 mg IV infusions 15 days apart (Retreatment Arm B). All participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve DAS28-CRP ≤3.2 After the First Course of Treatment</title>
          <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.</description>
          <population>ITT population</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" lower_limit="25.4">Upper limit of the 95% CI for time to low disease activity could not be calculated due to an insufficient number of events occurring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve DAS28-CRP ≤3.2 After Retreatment</title>
        <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.</description>
        <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
        <population>ITT population; n=number of participants assessed at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve DAS28-CRP ≤3.2 After Retreatment</title>
          <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.</description>
          <population>ITT population; n=number of participants assessed at a given visit.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st retreatment (n=66,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="21.1">Upper limit of the 95% CI for time to low disease activity could not be calculated due to an insufficient number of events occurring.</measurement>
                    <measurement group_id="O2" value="22.1" lower_limit="14.1" upper_limit="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd retreatment (n=49,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="14.1" upper_limit="33.9"/>
                    <measurement group_id="O2" value="29.0" lower_limit="15.0">Upper limit of the 95% CI for time to low disease activity could not be calculated due to an insufficient number of events occurring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of DAS28-CRP Remission After the First Course of Treatment</title>
        <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP &lt;2.6=remission.</description>
        <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
        <population>ITT population; only participants with a response (DAS28-CRP &lt;2.6) during initial treatment (at any point) were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Group</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants were randomized to receive a single rituximab 1000 mg IV infusion (Retreatment Arm A) or 2 x rituximab 1000 mg IV infusions 15 days apart (Retreatment Arm B). All participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of DAS28-CRP Remission After the First Course of Treatment</title>
          <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP &lt;2.6=remission.</description>
          <population>ITT population; only participants with a response (DAS28-CRP &lt;2.6) during initial treatment (at any point) were included in the analysis.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="8.0" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of DAS28-CRP Remission After Retreatment</title>
        <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP &lt;2.6=remission.</description>
        <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
        <population>ITT population; only participants with a response (DAS28-CRP &lt;2.6) during retreatment (at any point) were included in the analysis. n=number of participants assessed at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of DAS28-CRP Remission After Retreatment</title>
          <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP &lt;2.6=remission.</description>
          <population>ITT population; only participants with a response (DAS28-CRP &lt;2.6) during retreatment (at any point) were included in the analysis. n=number of participants assessed at a given visit.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st retreatment (n=21,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="15.0" upper_limit="17.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="7.7" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd retreatment (n=17,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="8.0" upper_limit="16.3"/>
                    <measurement group_id="O2" value="8.0" lower_limit="8.0" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of DAS28-CRP ≤3.2 After the First Course of Treatment</title>
        <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.</description>
        <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
        <population>ITT population; only participants with a response (DAS28-CRP ≤3.2) during first course of treatment (at any point) were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Group</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants were randomized to receive a single rituximab 1000 mg IV infusion (Retreatment Arm A) or 2 x rituximab 1000 mg IV infusions 15 days apart (Retreatment Arm B). All participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of DAS28-CRP ≤3.2 After the First Course of Treatment</title>
          <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.</description>
          <population>ITT population; only participants with a response (DAS28-CRP ≤3.2) during first course of treatment (at any point) were included in the analysis.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="9.0" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of DAS28-CRP ≤3.2 After Retreatment</title>
        <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.</description>
        <time_frame>Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104</time_frame>
        <population>ITT population; only participants with a response (DAS28-CRP ≤3.2) during retreatment (at any point) were included in the analysis. n=number of participants assessed at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of DAS28-CRP ≤3.2 After Retreatment</title>
          <description>DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.</description>
          <population>ITT population; only participants with a response (DAS28-CRP ≤3.2) during retreatment (at any point) were included in the analysis. n=number of participants assessed at a given visit.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st retreatment (n=35,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" lower_limit="22.7" upper_limit="32.0"/>
                    <measurement group_id="O2" value="17.0" lower_limit="9.0" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd retreatment (n=29,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="8.0" upper_limit="32.1"/>
                    <measurement group_id="O2" value="16.0" lower_limit="9.0" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20%, 50%, and 70% Improvement (ACR20/ACR50/ACR70)</title>
        <description>ACR20/50/70 response defined as ≥20%, 50%, or 70% improvement, respectively, in TJC and SJC, and ≥20%, 50%, or 70% improvement, respectively, in at least 3 of 5 remaining ACR core measures: Patient Global Assessment of Pain, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity (on a visual analog scale [VAS]); Health Assessment Questionnaire-Disability Index (HAQ-DI); and CRP.</description>
        <time_frame>Week 24 of the initial treatment, 24 weeks after first retreatment, and 24 weeks after second retreatment</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20%, 50%, and 70% Improvement (ACR20/ACR50/ACR70)</title>
          <description>ACR20/50/70 response defined as ≥20%, 50%, or 70% improvement, respectively, in TJC and SJC, and ≥20%, 50%, or 70% improvement, respectively, in at least 3 of 5 remaining ACR core measures: Patient Global Assessment of Pain, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity (on a visual analog scale [VAS]); Health Assessment Questionnaire-Disability Index (HAQ-DI); and CRP.</description>
          <population>ITT Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR20: Initial Treatment, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6"/>
                    <measurement group_id="O2" value="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20: 1st Retreatment, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6"/>
                    <measurement group_id="O2" value="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20: 2nd Retreatment, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.1"/>
                    <measurement group_id="O2" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50: Initial Treatment, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50: 1st Retreatment, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50: 2nd Retreatment, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6"/>
                    <measurement group_id="O2" value="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70: Initial Treatment, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                    <measurement group_id="O2" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70: 1st Retreatment, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70: 2nd Retreatment, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Response During Initial Treatment by European League Against Rheumatism (EULAR) Category</title>
        <description>DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders = change from baseline &gt;1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline &gt;1.2 with a DAS28 score of &gt;3.2 to ≤ 5.1 or change from baseline &gt;0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline &gt;0.6 and ≤ 1.2 with a DAS28 score of &gt;5.1.</description>
        <time_frame>Day 15, Weeks 6, 12, and 24</time_frame>
        <population>Overall population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Group</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants were randomized to receive a single rituximab 1000 mg IV infusion (Retreatment Arm A) or 2 x rituximab 1000 mg IV infusions 15 days apart (Retreatment Arm B). All participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Nonrandomized Group</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15, methylprednisolone 100 mg IV at 30 minutes before each rituximab infusion, and MTX ≥10 mg/week by mouth or parenterally throughout treatment course.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Response During Initial Treatment by European League Against Rheumatism (EULAR) Category</title>
          <description>DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders = change from baseline &gt;1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline &gt;1.2 with a DAS28 score of &gt;3.2 to ≤ 5.1 or change from baseline &gt;0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline &gt;0.6 and ≤ 1.2 with a DAS28 score of &gt;5.1.</description>
          <population>Overall population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good response: Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good response: Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good response: Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good response: Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate response: Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate response: Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate response: Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate response: Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response: Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response: Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response: Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response: Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Response During Retreatment by EULAR Category</title>
        <description>DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders = change from baseline &gt;1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline &gt;1.2 with a DAS28 score of &gt;3.2 to ≤ 5.1 or change from baseline &gt;0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline &gt;0.6 and ≤ 1.2 with a DAS28 score of &gt;5.1.</description>
        <time_frame>Week 24, 24 weeks after 1st retreatment, 24 weeks after 2nd retreatment</time_frame>
        <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Response During Retreatment by EULAR Category</title>
          <description>DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders = change from baseline &gt;1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline &gt;1.2 with a DAS28 score of &gt;3.2 to ≤ 5.1 or change from baseline &gt;0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline &gt;0.6 and ≤ 1.2 with a DAS28 score of &gt;5.1.</description>
          <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good response: Week 24 (n=70,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good response: 1st retreatment (n=66,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good response: 2nd retreatment (n=43,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate response: Week 24 (n=70,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate response: 1st retreatment (n=66,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate response: 2nd retreatment (n=43,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response: Week 24 (n=70,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response: 1st retreatment (n=66,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response: 2nd retreatment (n=43,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Rheumatoid Factor (RF) at 24 Weeks After Treatment</title>
        <description>RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 international units per milliliter (IU/mL) is considered positive.</description>
        <time_frame>Week 24 of the initial treatment, 24 weeks after first re-treatment, and 24 weeks after second retreatment</time_frame>
        <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rheumatoid Factor (RF) at 24 Weeks After Treatment</title>
          <description>RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 international units per milliliter (IU/mL) is considered positive.</description>
          <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative: Initial treatment, Week 24 (n=69,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="273.09"/>
                    <measurement group_id="O2" value="38.0" spread="408.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive: Initial treatment, Week 24 (n=69,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" spread="114.63"/>
                    <measurement group_id="O2" value="62.0" spread="386.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative: 1st Retreatment, Week 24 (n=44,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="79.14"/>
                    <measurement group_id="O2" value="48.8" spread="65.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive: 1st Retreatment, Week 24 (n=44,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" spread="75.68"/>
                    <measurement group_id="O2" value="51.2" spread="41.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative: 2nd retreatment, Week 24 (n=15,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive: 2nd retreatment, Week 24 (n=15,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3"/>
                    <measurement group_id="O2" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at 24 Weeks After Treatment</title>
        <description>Anti-CCP antibodies are auto antibodies (antibodies directed against 1 or more of an individual’s own proteins) that are frequently detected in the blood of rheumatoid arthritis participants. Anti-CCP antibodies value higher than 10 U/mL is considered positive.</description>
        <time_frame>Week 24 of the initial treatment, 24 weeks after first re-treatment, and 24 weeks after second retreatment</time_frame>
        <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at 24 Weeks After Treatment</title>
          <description>Anti-CCP antibodies are auto antibodies (antibodies directed against 1 or more of an individual’s own proteins) that are frequently detected in the blood of rheumatoid arthritis participants. Anti-CCP antibodies value higher than 10 U/mL is considered positive.</description>
          <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative: Initial treatment, Week 24 (n=69,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                    <measurement group_id="O2" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive: Initial treatment, Week 24 (n=69,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6"/>
                    <measurement group_id="O2" value="77.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative: 1st Retreatment, Week 24 (n=44,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive: 1st Retreatment, Week 24 (n=44,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3"/>
                    <measurement group_id="O2" value="79.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative: 2nd retreatment, Week 24 (n=15,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive: 2nd retreatment, Week 24 (n=15,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7"/>
                    <measurement group_id="O2" value="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Global Assessment of Disease Activity</title>
        <description>The Physician’s Global Assessment of disease activity is assessed on a 0 to 100 millimeter (mm) horizontal VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as “no disease activity” (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as “maximum disease activity” (maximum arthritis disease activity). Physicians were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high disease activity).</description>
        <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Assessment of Disease Activity</title>
          <description>The Physician’s Global Assessment of disease activity is assessed on a 0 to 100 millimeter (mm) horizontal VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as “no disease activity” (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as “maximum disease activity” (maximum arthritis disease activity). Physicians were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high disease activity).</description>
          <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial treatment, Day 1 (n=70,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" spread="15.0"/>
                    <measurement group_id="O2" value="64.1" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial treatment, Week 24 (n=69,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" spread="18.6"/>
                    <measurement group_id="O2" value="27.2" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before 1st retreatment (n=64,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="17.4"/>
                    <measurement group_id="O2" value="26.9" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Day 1 (n=60,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" spread="20.8"/>
                    <measurement group_id="O2" value="43.3" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12 (n=56,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" spread="18.8"/>
                    <measurement group_id="O2" value="28.4" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=60,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" spread="19.1"/>
                    <measurement group_id="O2" value="24.8" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment of Disease Activity</title>
        <description>The Patient's Global Assessment of Disease Activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as “no disease activity” (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as “maximum disease activity” (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).</description>
        <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Re-treatment Arm A: Single 1000 mg IV Rituximab</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment of Disease Activity</title>
          <description>The Patient's Global Assessment of Disease Activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as “no disease activity” (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as “maximum disease activity” (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).</description>
          <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial treatment, Day 1 (n=70,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" spread="20.4"/>
                    <measurement group_id="O2" value="64.2" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial treatment, Week 24 (n=70,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" spread="22.3"/>
                    <measurement group_id="O2" value="32.6" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before 1st retreatment (n=65,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="19.6"/>
                    <measurement group_id="O2" value="34.7" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Day 1 (n=65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7" spread="21.2"/>
                    <measurement group_id="O2" value="46.6" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12 (n=63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="21.2"/>
                    <measurement group_id="O2" value="34.5" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=64,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" spread="24.6"/>
                    <measurement group_id="O2" value="34.1" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Assessment of Pain</title>
        <description>The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as “no pain” and the right-hand extreme equals 100 mm as “unbearable pain&quot;. Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high pain levels).</description>
        <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Assessment of Pain</title>
          <description>The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as “no pain” and the right-hand extreme equals 100 mm as “unbearable pain&quot;. Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high pain levels).</description>
          <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial Treatment, Day 1 (n=70,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" spread="22.3"/>
                    <measurement group_id="O2" value="60.1" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial Treatment, Week 24 (n=70,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" spread="22.0"/>
                    <measurement group_id="O2" value="30.0" spread="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before 1st retreatment (n=65,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" spread="21.3"/>
                    <measurement group_id="O2" value="32.9" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st re-treatment, Day 1 (n=65,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" spread="21.5"/>
                    <measurement group_id="O2" value="45.2" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12 (n=64,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" spread="21.4"/>
                    <measurement group_id="O2" value="33.9" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=64,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" spread="24.6"/>
                    <measurement group_id="O2" value="34.3" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Assessment of Fatigue</title>
        <description>Participants were asked to rate their level of fatigue over the last 7 days on a 100-mm VAS. The left-hand extreme of the line equals 0 mm, and is described as “no fatigue” and the right-hand extreme equals 100 mm as “extreme fatigue&quot;. Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high levels of fatigue).</description>
        <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Assessment of Fatigue</title>
          <description>Participants were asked to rate their level of fatigue over the last 7 days on a 100-mm VAS. The left-hand extreme of the line equals 0 mm, and is described as “no fatigue” and the right-hand extreme equals 100 mm as “extreme fatigue&quot;. Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high levels of fatigue).</description>
          <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial Treatment, Day 1 (n=70,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.1" spread="21.4"/>
                    <measurement group_id="O2" value="62.0" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial Treatment, Week 24 (n=70,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" spread="24.2"/>
                    <measurement group_id="O2" value="39.8" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before 1st retreatment (n=64,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5" spread="20.8"/>
                    <measurement group_id="O2" value="41.2" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Day 1 (n=65,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6" spread="22.6"/>
                    <measurement group_id="O2" value="51.7" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12 (n=63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" spread="23.0"/>
                    <measurement group_id="O2" value="45.3" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=64,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0" spread="25.3"/>
                    <measurement group_id="O2" value="38.9" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cortisone Intake AUC (Time- and Weight-Weighted)</title>
        <description>All cortisone intakes (in mg) were taken into account (oral, IV [including the cortisone administration before the rituximab infusion], intramuscular, and intra-articular).</description>
        <time_frame>Day 1 (each infusion), Week 24, Week 104</time_frame>
        <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Cortisone Intake AUC (Time- and Weight-Weighted)</title>
          <description>All cortisone intakes (in mg) were taken into account (oral, IV [including the cortisone administration before the rituximab infusion], intramuscular, and intra-articular).</description>
          <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>mg*week</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 to Week 104 (n=69,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.06"/>
                    <measurement group_id="O2" value="0.09" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment to Week 104 (n=65,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.06"/>
                    <measurement group_id="O2" value="0.09" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 to Week 104 (n=69,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.06"/>
                    <measurement group_id="O2" value="0.09" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1 to Week 104</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.389</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>1st retreatment to Week 104</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.374</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Weel 24 to Week 104</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.277</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Mean Dose of Cortisone Between Week 24 and Week 104</title>
        <description>All cortisone intakes were taken into account, including oral, IV (including the cortisone administration before the rituximab infusion), intramuscular and intra-articular.</description>
        <time_frame>Week 24 to Week 104</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Mean Dose of Cortisone Between Week 24 and Week 104</title>
          <description>All cortisone intakes were taken into account, including oral, IV (including the cortisone administration before the rituximab infusion), intramuscular and intra-articular.</description>
          <population>ITT population</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total cortisone: Week 24 to Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2542.9" spread="2085.6"/>
                    <measurement group_id="O2" value="2842.5" spread="2124.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral cortisone: Week 24 to Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2384.0" spread="2092.6"/>
                    <measurement group_id="O2" value="2425.1" spread="2046.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV cortisone: Week 24 to Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199.1" spread="92.3"/>
                    <measurement group_id="O2" value="384.9" spread="193.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total cortisone: Week 24 to Week 104</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.278</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Oral cortisone: Week 24 to Week 104</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.887</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IV cortisone: Week 24 to Week 104</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HAQ-DI Scores</title>
        <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.</description>
        <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>HAQ-DI Scores</title>
          <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.</description>
          <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial treatment, Day 1 (n=70,69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.61"/>
                    <measurement group_id="O2" value="1.75" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial treatment, Week 24 (n=68,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.67"/>
                    <measurement group_id="O2" value="1.31" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before 1st retreatment (n=64,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="0.67"/>
                    <measurement group_id="O2" value="1.35" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Day 1 (n=58,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.68"/>
                    <measurement group_id="O2" value="1.42" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12 (n=62,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.66"/>
                    <measurement group_id="O2" value="1.33" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=63,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="0.72"/>
                    <measurement group_id="O2" value="1.32" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form 12 (SF-12) Physical Health Composite Score</title>
        <description>Physical and Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
        <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form 12 (SF-12) Physical Health Composite Score</title>
          <description>Physical and Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
          <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial treatment, Day 1 (n=62,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.11" spread="7.55"/>
                    <measurement group_id="O2" value="31.07" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial Tteatment, Week 24 (n=63,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.81" spread="8.39"/>
                    <measurement group_id="O2" value="40.05" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before 1st retreatment (n=21,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.44" spread="8.45"/>
                    <measurement group_id="O2" value="39.52" spread="9.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Day 1 (n=47,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.57" spread="6.75"/>
                    <measurement group_id="O2" value="35.81" spread="8.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12 (n=13,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.36" spread="9.30"/>
                    <measurement group_id="O2" value="38.05" spread="10.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=40,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.53" spread="7.75"/>
                    <measurement group_id="O2" value="36.86" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-12 Mental Health Composite Score</title>
        <description>Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
        <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>SF-12 Mental Health Composite Score</title>
          <description>Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
          <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial treatment, Day 1 (n=62,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.03" spread="10.03"/>
                    <measurement group_id="O2" value="37.13" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial treatment, Week 24 (n=63,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.08" spread="9.74"/>
                    <measurement group_id="O2" value="40.99" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before 1st retreatment (n=21,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.94" spread="9.94"/>
                    <measurement group_id="O2" value="41.57" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Day 1 (n=47,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.87" spread="10.53"/>
                    <measurement group_id="O2" value="38.52" spread="7.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12 (n=13,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.84" spread="11.36"/>
                    <measurement group_id="O2" value="34.69" spread="11.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=40,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.90" spread="10.61"/>
                    <measurement group_id="O2" value="41.60" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Outcomes Study Sleep Scale (MOS-Sleep) Composite Sleep Problems 6 (SLP6) Index</title>
        <description>The MOS Sleep Scale measures most constructs of sleep. The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities. The SLP6 index is comprised of 6 items: provides a summary of sleep problems and contains questions from the sleep disturbance, sleep adequacy, respiratory impairment, and somnolence domains. The SLP6 index score ranges between 0 and 100, with higher values corresponding to more sleep problems.</description>
        <time_frame>Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population;n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Medical Outcomes Study Sleep Scale (MOS-Sleep) Composite Sleep Problems 6 (SLP6) Index</title>
          <description>The MOS Sleep Scale measures most constructs of sleep. The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities. The SLP6 index is comprised of 6 items: provides a summary of sleep problems and contains questions from the sleep disturbance, sleep adequacy, respiratory impairment, and somnolence domains. The SLP6 index score ranges between 0 and 100, with higher values corresponding to more sleep problems.</description>
          <population>ITT population;n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial treatment, Day 1 (n=68,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.15" spread="15.32"/>
                    <measurement group_id="O2" value="49.89" spread="15.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial treatment, Week 24 (n=65,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.73" spread="14.90"/>
                    <measurement group_id="O2" value="40.50" spread="17.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before 1st retreatment (n=62,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.44" spread="13.97"/>
                    <measurement group_id="O2" value="41.27" spread="17.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Day 1 (n=57,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.25" spread="16.53"/>
                    <measurement group_id="O2" value="44.94" spread="16.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12 (n=61,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.64" spread="14.41"/>
                    <measurement group_id="O2" value="43.74" spread="18.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=63,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.74" spread="15.35"/>
                    <measurement group_id="O2" value="40.08" spread="16.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Acceptable Disease Activity Symptom State Assessed Using Patient Acceptable and Unacceptable Symptom State (PASS)</title>
        <description>Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of disease activity they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered &quot;unacceptable&quot;.</description>
        <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Acceptable Disease Activity Symptom State Assessed Using Patient Acceptable and Unacceptable Symptom State (PASS)</title>
          <description>Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of disease activity they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered &quot;unacceptable&quot;.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4"/>
                    <measurement group_id="O2" value="75.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5"/>
                    <measurement group_id="O2" value="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment of Disease Activity in Participants Reporting Acceptable Symptoms Using PASS</title>
        <description>The Patient's Global Assessment of Disease Activity assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as “no disease activity” (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as “maximum disease activity” (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).</description>
        <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population; only participants with 'acceptable' symptom state assessed using PASS were included in the analysis. n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment of Disease Activity in Participants Reporting Acceptable Symptoms Using PASS</title>
          <description>The Patient's Global Assessment of Disease Activity assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as “no disease activity” (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as “maximum disease activity” (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).</description>
          <population>ITT population; only participants with 'acceptable' symptom state assessed using PASS were included in the analysis. n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (n=47,52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" spread="18.5"/>
                    <measurement group_id="O2" value="28.4" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12 (n=44,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" spread="16.6"/>
                    <measurement group_id="O2" value="27.3" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=43,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="19.5"/>
                    <measurement group_id="O2" value="25.7" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Minimum Clinically Important Improvement (MCII) in Disease Activity</title>
        <description>Participants were asked how their disease activity had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse-more disease activity.</description>
        <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Minimum Clinically Important Improvement (MCII) in Disease Activity</title>
          <description>Participants were asked how their disease activity had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse-more disease activity.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4"/>
                    <measurement group_id="O2" value="81.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6"/>
                    <measurement group_id="O2" value="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="66.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Assessment of Disease Activity in Participants With MCII</title>
        <description>The Patient's Global Assessment of Disease Activity was assessed in participants reporting MCII on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as “no disease activity” (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as “maximum disease activity” (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).</description>
        <time_frame>Baseline, Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population; only participants with MCII were included in the analysis. n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Assessment of Disease Activity in Participants With MCII</title>
          <description>The Patient's Global Assessment of Disease Activity was assessed in participants reporting MCII on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as “no disease activity” (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as “maximum disease activity” (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).</description>
          <population>ITT population; only participants with MCII were included in the analysis. n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (n=49,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" spread="20.7"/>
                    <measurement group_id="O2" value="-4.6" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12 (n=38,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="16.0"/>
                    <measurement group_id="O2" value="-9.2" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=40,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="17.8"/>
                    <measurement group_id="O2" value="-2.9" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Acceptable Symptom State in Functioning Assessed Using PASS</title>
        <description>Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of function they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of function they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered &quot;unacceptable&quot;.</description>
        <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Acceptable Symptom State in Functioning Assessed Using PASS</title>
          <description>Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of function they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of function they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered &quot;unacceptable&quot;.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2"/>
                    <measurement group_id="O2" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9"/>
                    <measurement group_id="O2" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2"/>
                    <measurement group_id="O2" value="62.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HAQ-DI Scores in Participants Reporting Acceptable Function Using PASS</title>
        <description>HAQ-DI was assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours). HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.</description>
        <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population; only participants with 'acceptable' symptom state assessed using PASS were included in the analysis. n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>HAQ-DI Scores in Participants Reporting Acceptable Function Using PASS</title>
          <description>HAQ-DI was assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours). HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.</description>
          <population>ITT population; only participants with 'acceptable' symptom state assessed using PASS were included in the analysis. n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (n=46,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.69"/>
                    <measurement group_id="O2" value="1.16" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12 (n=44,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="0.70"/>
                    <measurement group_id="O2" value="1.08" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=40,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="0.75"/>
                    <measurement group_id="O2" value="1.08" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With MCII in Functioning</title>
        <description>Participants were asked how their functioning had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse.</description>
        <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With MCII in Functioning</title>
          <description>Participants were asked how their functioning had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4"/>
                    <measurement group_id="O2" value="76.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0"/>
                    <measurement group_id="O2" value="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5"/>
                    <measurement group_id="O2" value="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI in Participants With MCII</title>
        <description>HAQ-DI was assessed in participants with MCII. HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.</description>
        <time_frame>Baseline, Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population; only participants with MCII were included in the analysis. n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI in Participants With MCII</title>
          <description>HAQ-DI was assessed in participants with MCII. HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.</description>
          <population>ITT population; only participants with MCII were included in the analysis. n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (n=47,52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.46"/>
                    <measurement group_id="O2" value="-0.06" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12 (n=38,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.30"/>
                    <measurement group_id="O2" value="-0.11" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=38,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.24"/>
                    <measurement group_id="O2" value="-0.09" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Acceptable Symptom State in Pain Assessed Using PASS</title>
        <description>Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of pain they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered &quot;unacceptable&quot;.</description>
        <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Acceptable Symptom State in Pain Assessed Using PASS</title>
          <description>Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of pain they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered &quot;unacceptable&quot;.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2"/>
                    <measurement group_id="O2" value="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9"/>
                    <measurement group_id="O2" value="61.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment of Pain in Participants Reporting Acceptable Symptoms Using PASS</title>
        <description>Patient Global Assessment of Pain assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as “no pain” and the right-hand extreme equals 100 mm as “unbearable pain”. Higher values correspond to worst state of participant (high pain levels).</description>
        <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population; only participants with 'acceptable' symptom state assessed using PASS were included in the analysis. n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment of Pain in Participants Reporting Acceptable Symptoms Using PASS</title>
          <description>Patient Global Assessment of Pain assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as “no pain” and the right-hand extreme equals 100 mm as “unbearable pain”. Higher values correspond to worst state of participant (high pain levels).</description>
          <population>ITT population; only participants with 'acceptable' symptom state assessed using PASS were included in the analysis. n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (n=46,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="16.2"/>
                    <measurement group_id="O2" value="26.4" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12 (n=40,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" spread="17.3"/>
                    <measurement group_id="O2" value="27.6" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=43,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="20.1"/>
                    <measurement group_id="O2" value="25.1" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With MCII in Pain</title>
        <description>Participants were asked how their pain had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse pain.</description>
        <time_frame>Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With MCII in Pain</title>
          <description>Participants were asked how their pain had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse pain.</description>
          <population>ITT population; n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (n=63,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2"/>
                    <measurement group_id="O2" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12 (n=59,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2"/>
                    <measurement group_id="O2" value="69.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=61,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9"/>
                    <measurement group_id="O2" value="61.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Assessment of Pain in Participants With MCII</title>
        <description>The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as “no pain” and the right-hand extreme equals 100 mm as “unbearable pain&quot;. Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high pain levels).</description>
        <time_frame>Baseline, Week 24, 12 and 24 weeks after 1st retreatment</time_frame>
        <population>ITT population; only participants with MCII were included in the analysis. n=number of participants assessed for the specified parameter at a given visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
            <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Assessment of Pain in Participants With MCII</title>
          <description>The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as “no pain” and the right-hand extreme equals 100 mm as “unbearable pain&quot;. Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high pain levels).</description>
          <population>ITT population; only participants with MCII were included in the analysis. n=number of participants assessed for the specified parameter at a given visit.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (n=48,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.5" spread="21.0"/>
                    <measurement group_id="O2" value="-4.3" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 12 (n=39,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="13.6"/>
                    <measurement group_id="O2" value="-8.9" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st retreatment, Week 24 (n=42,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="24.3"/>
                    <measurement group_id="O2" value="-3.2" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 104 weeks; related serious adverse events (SAEs) were collected and reported regardless of time elapsed from last dose of study drug; unrelated SAEs were collected during the study and for up to 24 weeks after last dose of study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Randomized Retreatment Arm A: Rituximab 1000 mg</title>
          <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received one additional infusion of rituximab 1000 mg IV. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and MTX ≥10 mg/week by mouth or parenteral throughout course of treatment.</description>
        </group>
        <group group_id="E2">
          <title>Randomized Retreatment Arm B: Rituximab 1000 mg x 2</title>
          <description>Participants received rituximab 1000 mg IV on Days 1 and 15. After Week 24, if DAS28 was &gt;3.2, participants received two additional infusions of rituximab 1000 mg IV, 15 days apart. Participants received methylprednisolone 100 mg IV 30 minutes before each rituximab infusion and ≥10 mg/week MTX by mouth or parenteral throughout course of treatment.</description>
        </group>
        <group group_id="E3">
          <title>Nonrandomized: Rituximab 1000 mg</title>
          <description>Participants received rituximab 1000 mg IV on Days 1 and 15, methylprednisolone 100 mg IV at 30 minutes before each rituximab infusion, and MTX ≥10 mg/week by mouth or parenterally throughout treatment course.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Perianal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Prostate infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bone erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rheumatoid nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Thrombocythaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Keratoconjunctivitis sicca</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Retinopathy hypertensive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infusion site phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sense of oppression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cytolytic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Allergy to chemicals</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rhinotracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sinobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Campylobacter intestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infected sebaceous cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Perianal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Prostate infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bacteria urine identified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Deoxyribonucleic acid (DNA) antibody positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Electrocardiogram repolarisation abnormality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus non-insulin-dependent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bone erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rheumatoid nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Toe deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vaginal papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cervical root pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Larynx irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Eczema nummular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Apicectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Corneal operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Skin neoplasm excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Therapy regimen changed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Nonserious adverse events (AEs) presented in this record include all AEs reported during the study, not just nonserious events.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-LaRoche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

